Repligen Corporation (RGEN) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $115.27 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk).
Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $115.27 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierXCell ATF® systems suppliers10-K Item 1A: 'only a small number of suppliers are currently qualified to supply materials for the XCell ATF® systems'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $115.27 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $107.20. Score 5.5/10, moderate confidence.
Take-profit target: $161.80 (+40.4% upside). Prior stop was $107.20. Stop-loss: $107.20.
Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk); Negative momentum.
Repligen Corporation trades at a P/E of 131.5 (forward 44.9). TrendMatrix value score: 5.2/10. Verdict: Sell.
28 analysts cover RGEN with a consensus score of 4.1/5. Average price target: $180.
What does Repligen Corporation do?Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four...
Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and integrators worldwide. 39.5% of 2025 revenues were denominated in foreign currencies.